---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-426828"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2026-10-20T21:04:33+00:00"
generated_at: "2026-10-20T21:06:03.463321+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen closes $95.1M second tranche at $11.60/share; cash runway extended into 2029

## Summary
- Gross proceeds of ~$95.1M: 5,741,605 shares at $11.60, 2,456,500 pre-funded warrants at $11.5999, and Series E warrants for 4,099,052 shares at $11.54 strike.
- Second closing milestone triggered by FDA clearance of the SZN-8141 IND on October 2, 2026, under the March 24, 2025 securities purchase agreement.
- Post-closing capitalization: ~17.8M common shares outstanding, 3.8M issuable on pre-funded warrants, 9.1M on common warrants (mostly $11.54 strike, expiring 2029-2031).
- Cash, equivalents and marketable securities expected to fund runway into 2029, including the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143.
- Must file a resale S-3 within 30 days of closing and seek effectiveness within 90 days (120 if full SEC review).

## SEC filing metadata
- accession: 0001193125-26-426828
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2026-10-20T21:04:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/0001193125-26-426828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/srzn-20261020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-426828
- JSON: https://secwatch.observer/filing/0001193125-26-426828.json
- Plain text: https://secwatch.observer/filing/0001193125-26-426828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.